Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Hammel

Showing results (171-180 of 241) with videos related to

Pageof 25
Sort By:
Therapeutic Advances in Medical Oncology|January 26, 2023
Identification of a large intra-exonic deletion in <i>BRCA2</i> exon 18 in a pancreatic ductal adenocarcinomaInès Debbabi, Sophie Vacher, Cindy Neuzillet, et al.
Neuroendocrinology|February 14, 2019
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score AnalysesLouis de Mestier, Thomas Walter, Hedia Brixi, et al.
Pancreas|June 27, 2008
Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic featuresOlivier Corcos, Anne Couvelard, Sophie Giraud, et al.
Neuroendocrinology|August 21, 2019
Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine TumoursAnna Pellat, Thomas Walter, Jérémy Augustin, et al.
Gut|October 16, 2010
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)Laetitia Dahan, Frank Bonnetain, Marc Ychou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II studyJean-Luc Van Laethem, Pascal Hammel, Françoise Mornex, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 29, 2008
Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up studyPierre-Emmanuel Rautou, Phillippe Lévy, Marie-Pierre Vullierme, et al.
Oncotarget|November 17, 2016
Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR groupStéphane Oudard, Reza Elaidi, Mara Brizard, et al.
Clinics and Research in Hepatology and Gastroenterology|March 4, 2021
Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO groupClémence Breton, Antoine Meyer, David Malka, et al.
British Journal of Cancer|July 13, 2016
Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)Dewi Vernerey, Florence Huguet, Angélique Vienot, et al.
Pageof 25

Showing results (171-180 of 241) with videos related to

Sort By:
Pageof 25
Therapeutic Advances in Medical Oncology|January 26, 2023
Identification of a large intra-exonic deletion in <i>BRCA2</i> exon 18 in a pancreatic ductal adenocarcinomaInès Debbabi, Sophie Vacher, Cindy Neuzillet, et al.
Neuroendocrinology|February 14, 2019
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score AnalysesLouis de Mestier, Thomas Walter, Hedia Brixi, et al.
Pancreas|June 27, 2008
Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic featuresOlivier Corcos, Anne Couvelard, Sophie Giraud, et al.
Neuroendocrinology|August 21, 2019
Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine TumoursAnna Pellat, Thomas Walter, Jérémy Augustin, et al.
Gut|October 16, 2010
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)Laetitia Dahan, Frank Bonnetain, Marc Ychou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II studyJean-Luc Van Laethem, Pascal Hammel, Françoise Mornex, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 29, 2008
Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up studyPierre-Emmanuel Rautou, Phillippe Lévy, Marie-Pierre Vullierme, et al.
Oncotarget|November 17, 2016
Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR groupStéphane Oudard, Reza Elaidi, Mara Brizard, et al.
Clinics and Research in Hepatology and Gastroenterology|March 4, 2021
Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO groupClémence Breton, Antoine Meyer, David Malka, et al.
British Journal of Cancer|July 13, 2016
Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)Dewi Vernerey, Florence Huguet, Angélique Vienot, et al.
Pageof 25